Cargando…
γδ T cells in immunotherapies for B-cell malignancies
Despite the advancements in therapy for B cell malignancies and the increase in long–term survival of patients, almost half of them lead to relapse. Combinations of chemotherapy and monoclonal antibodies such as anti-CD20 leads to mixed outcomes. Recent developments in immune cell-based therapies ar...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10325712/ https://www.ncbi.nlm.nih.gov/pubmed/37426670 http://dx.doi.org/10.3389/fimmu.2023.1200003 |